Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05095935 · ClinicalTrials.gov registry record
Medtronic Signia SDR Product Surveillance Registry
A clinical trial, sponsored by Medtronic.
- Completed
- Registry status
- 430
- Enrollment target
NCT05095935: Completed study, sponsored by Medtronic.
NCT05095935 is a clinical trial that has completed, run by Medtronic. The registered enrollment target is 430 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05095935 has completed, sponsored by Medtronic.
- COMPLETED
- Registry status
- 430 participants
- Enrollment target
Study Summary
The purpose of the registry is to confirm the safety and performance of the Signia™ Small Diameter Reload (SDR) when used in surgical procedures in a real-world setting in patients receiving surgery for indicated thoracic, abdominal, and pediatric applications, intraoperatively.
Primary Outcome
* Adult Thoracic: incidence of intraoperative hemostatic intervention related to the transection of pulmonary arteries and veins. * Adult Abdominal: incidence of intraoperative hemostatic intervention related to the transection of renal arteries and veins. * Pediatric Abdominal: incidence of intraoperative hemostatic and leak intervention related to the transection of the appendiceal stump and mesoappendix (simple acute appendicitis).
Interventions
- OTHER N/A observational registry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2021-08-10 |
| Est. Completion | 2024-10-01 |
What the finished NCT05095935 record still lists
NCT05095935 is an observational study that tracks outcomes without assigning an intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which N/A observational registry is the first listed.
NCT05095935 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05095935 about?
NCT05095935 is a clinical study titled "Medtronic Signia SDR Product Surveillance Registry". The purpose of the registry is to confirm the safety and performance of the Signia™ Small Diameter Reload (SDR) when used in surgical procedures in a real-world setting in patients receiving surgery for indicated thoracic, abdominal, and pediatric applications, intraoperatively.
What is the current status of trial NCT05095935?
This trial is currently completed. The enrollment target is 430 participants. The study started on 2021-08-10. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT05095935?
The interventions under investigation include: N/A observational registry (OTHER).
Who is sponsoring clinical trial NCT05095935?
This trial is sponsored by Medtronic, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
- NCT05844891 · 430 participants · NA
Telehealth-Enhanced Asthma Care for Home After the Emergency Room
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI